MGB Biopharma, established to develop a new class of anti-infective medicines, has raised the cash in a round which included the Scottish Investment Bank.

UK-based biopharmaceutical company MGB Biopharma has secured £4m ($6.4m) in funding with involvement from Scottish Investment Bank, the investment arm of Scottish Enterprise.

Scotland-based business angel syndicate Archangels led the £2.7m equity portion of the round, which also featured venture capital firms Barwell and TRI Cap alongside Scottish Investment Bank.

MGB develops anti-infectives to fight diseases that are resistant to antibiotics. The funds will be used to advance its lead antibacterial candidate, MGB-BP-3, into clinical development

Miroslav Ravic, chief executive…